Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPATH.L Regulatory News (PATH)

  • There is currently no data for PATH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further re the Acquisition of 75% of DT Ultravert

5 Nov 2020 07:00

RNS Number : 3105E
Path Investments plc
05 November 2020
 

 

Path Investments plc("Path" or the "Company")

 

Extension of and Amendment to Agreement for the Acquisition of 75% of DT Ultravert from Zoetic International plc

 

Path Investments plc (TIDM: PATH), the energy and natural resources investment company, is pleased to announce the extension of, and certain amendments to, its binding agreement with Zoetic International plc ("Zoetic") for the acquisition of its 75% ownership of DT Ultravert ("DTU").

 

As announced on 1 October 2020, Path has secured agreement for the purchase of 25% of DTU from Diversion Technologies LLC ("Diversion") and therefore the conclusion of the acquisition from Zoetic will unify DTU in one party's ownership for the first time. Path considers this will be a key factor in the successful marketing of DTU going forward.

 

The Company has previously announced that it is proceeding with preparation for publication of a prospectus relating to its acquisition of 100% of DTU from both Zoetic and Diversion and readmission of Path's ordinary shares to the standard segment of the Official List maintained by the Financial Conduct Authority and to trading on the Main Market of the London Stock Exchange ("Re-admission"). This is progressing, but to accommodate the time required to complete the matters associated with the Re-admission, the Company and Zoetic have agreed to extend the long stop date within the agreement. No such extension is required at this time for the agreement with Diversion.

 

In addition, Path and Zoetic have taken the opportunity to amend the consideration and structure of the transaction to match that agreed with Diversion pro-rata.

 

Firstly, in order to simplify the transaction, the Kansas assets will now be retained by Zoetic and accordingly they no longer form part of the transaction. The Company has today agreed with GasRock Limited that the conditional agreement announced by the Company on 5 October 2020 for their purchase of the Kansas assets is cancelled with immediate effect, at no cost to either party.

 

Secondly, the consideration for the acquisition of the 75% of DTU from Zoetic has been adjusted and will now be satisfied by the issue by Path to Zoetic of 30,000,000 ordinary shares in Path on Re-admission, together with the issue of 15,000,000 warrants to subscribe for ordinary shares in Path at any time from the first to the third anniversaries following completion of the acquisition at an exercise price of 1.5 pence per ordinary share. In return, Zoetic has agreed that no royalty payments will be made in respect of revenue earned by Path from DTU.

 

Completion of the transactions with Zoetic and Diversion are subject to a number of items, including the publication of a prospectus by Path prepared in accordance with the Prospectus Regulation Rules made under section 73A of the Financial Services and Markets Act 2000 (as amended) and approved by the UK Financial Conduct Authority under section 87A of Financial Services and Markets Act 2000 (as amended) and Re-admission.

 

Commenting, Christopher Theis CEO of Path, said: "We are pleased to have agreed the extension and amendment of our transaction with Zoetic. We now have a more balanced and simplified transaction structure which meets the needs of all parties and we look forward to completion of the transaction shortly. The removal of the ongoing royalty in return for the restructured consideration and retention of the Kansas assets by Zoetic creates a cleaner structure and one which is potentially more valuable to Path over the long term."

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. The public disclosure of this inside information was delayed pursuant to Article 17(4) MAR.

 

For further information please contact:

Path Investments plc

C/O IFC

Christopher Theis

IFC Advisory Limited (Financial PR & IR)

020 3934 6630

Tim Metcalfe

Zach Cohen

Grant Thornton UK LLP (Financial Adviser)

Jamie Barklem

020 7865 2692

Harrison Clarke

020 7184 4384

Keith, Bayley, Rogers & Co. Limited (Broker)

Brinsley Holman

07776 30 22 28

Graham Atthill-Beck

07506 43 41 07

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURBIBMTMTJMTMM
Date   Source Headline
7th Apr 20227:00 amRNSUpdate on Acquisition
5th Apr 20227:00 amRNSInvestor Presentation
1st Apr 20222:45 pmRNSResult of General Meeting
14th Mar 20221:09 pmRNSPublication of Prospectus, Notice of GM, Fundraise
1st Feb 20227:00 amRNSProposed Transaction Update
31st Dec 20217:00 amRNSProposed Transaction Update
18th Nov 20217:00 amRNSAppointment of Joint Broker
26th Oct 20217:00 amRNSProposed Transaction Update
13th Oct 20216:02 pmRNSCorrection: Holding(s) in Company
13th Oct 20214:52 pmRNSHolding(s) in Company
11th Oct 20217:00 amRNSBlock listing Interim Review
29th Sep 20217:00 amRNSInterim Results for the six months to 30 June 2021
28th Sep 20212:45 pmRNSResult of AGM
22nd Sep 20212:41 pmRNSFurther secured loan provided to DG Innovate
9th Sep 20216:01 pmRNSHolding(s) in Company
2nd Sep 20217:00 amRNSNotice of AGM
18th Aug 202111:54 amRNSCorrection: Holding(s) in Company
18th Aug 20217:00 amRNSHolding(s) in Company
13th Aug 20217:45 amRNSProposed Acquisition of DG Innovate & Suspension
14th Jul 20215:23 pmRNSHolding(s) in Company
14th Jul 20212:39 pmRNSHolding(s) in Company
24th Jun 20217:00 amRNSFinal Results for the Year Ended 31 December 2020
16th Jun 20217:00 amRNSHolding(s) in Company
8th Jun 202111:49 amRNSHolding(s) in Company
7th Jun 202112:04 pmRNSHolding(s) in Company
9th Apr 202110:03 amRNSHolding(s) in Company
9th Apr 20217:00 amRNSBlock Listing
1st Apr 20215:02 pmRNSHolding(s) in Company
31st Mar 20219:55 amRNSTotal Voting Rights
24th Mar 20212:06 pmRNSDirector/PDMR Share Transaction
19th Mar 20218:53 amRNSHolding(s) in Company
12th Mar 20215:36 pmRNSAdmission of previously issued shares
12th Mar 202112:50 pmRNSPublication of Prospectus
8th Mar 202111:05 amRNSSecond Price Monitoring Extn
8th Mar 202111:00 amRNSPrice Monitoring Extension
1st Mar 20214:41 pmRNSSecond Price Monitoring Extn
1st Mar 20214:36 pmRNSPrice Monitoring Extension
26th Feb 20212:06 pmRNSSecond Price Monitoring Extn
26th Feb 20212:00 pmRNSPrice Monitoring Extension
26th Feb 20217:00 amRNSEquity Fundraise Update
19th Feb 20217:00 amRNS£3.5 million Equity Fundraise
15th Feb 20212:00 pmRNSTermination of DTU Acquisition
3rd Dec 20209:44 amRNSSubscription for £55,000 of Convertible Loan Stock
5th Nov 20207:00 amRNSFurther re the Acquisition of 75% of DT Ultravert
8th Oct 20209:55 amRNSOption Surrender and Issue of Replacement Options
5th Oct 20207:00 amRNSProposed sale of Kansas Land Leases and equipment
1st Oct 202011:41 amRNSFurther re the Acquisition of DT Ultravert
30th Sep 20207:00 amRNSBoard Changes & Acquisition of Deferred Shares
10th Sep 20201:30 pmRNSInterim Results for the six months to 30 June 2020
10th Sep 20201:15 pmRNSFinal Results for the Year Ended 31 December 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.